WDHD1 and cancer: In paclitaxel analysis, we found that the IC50 values of paclitaxel were significantly lower in the groups with high WDHD1 expression compared to those with low expression across all 10 types of cancer, suggesting that paclitaxel treatment may confer greater benefits to patients with high WDHD1 expression (Fig. 7B).